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Conclusions. Androgens therapy improved the anemia inRandomized prospective comparison between erythropoietin
elderly male CAPD patients in a similar manner to that ob-and androgens in CAPD patients.
served with rHuEPO. Furthermore, compared with rHuEPO,Background. Anemia and malnutrition are significant com-
androgen administration was associated with beneficial effectsplications in peritoneal dialysis (PD) patients. Previous studies
on nutritional status. The mechanism of action of androgensin hemodialysis have shown that androgens are effective as
on hematologic and nutritional parameters might be mediated,therapy for anemia; however, this has not been tested in a
at least in part, by IGF-1.randomized prospective trial in PD patients. Furthermore, the
anabolic properties of androgens may exert additional benefits
on the nutritional status in this population.
Methods. Twenty-seven stable male patients over 50 years
Peritoneal dialysis (PD) is a well-established form ofwho were under maintenance continuous ambulatory perito-
renal replacement therapy. The overall number of pa-neal dialysis (CAPD) therapy were randomized to receive re-
combinant human erythropoietin (rHuEPO; N  14) or nan- tients treated with this technique has increased steadily
drolone decanoate (ND; 200 mg/week IM; N  13) as therapy over the last decades, and thus, by the end of 1996, PD
for anemia. The evolution of hematologic parameters and the patients accounted for approximately 14% of all dialysisimpact on both nutritional anthorpometric and biochemical
population [1]. However, despite the progressive accu-variables were evaluated after six months of treatment.
mulated experience and improvements in the PD tech-Results. Hemoglobin and hematocrit experienced similar in-
creases in both groups: from 8.5  0.9 g/dL and 25.8  2.7% nique some complications remain a concern for these
to 11.7  0.6 g/dL and 34.7  1.6% (P  0.001) in patients patients.
receiving rHuEPO, and from 8.9 0.8 and 27 2.2% to 11.8 Protein-energy malnutrition, which forms the back-0.4 g/dL and 35.1  1.5% (P  0.001) in subjects treated with
ground to many aspects of the uremic syndrome, is highlyND. At the end of the study, out of the diverse nutritional
variables included in this investigation, only weight and body prevalent in PD. In a cross-sectional multicenter study
mass index significantly increased in the rHuEPO group. Con- that evaluated the nutritional status in 224 patients under
versely, both anthropometric [weight, body mass index, triceps continuous ambulatory PD (CAPD), some degree of
skinfold, mid-arm circunference (MAC) and mid-arm muscle
malnutrition was documented in 40% of subjects, withcircunference (MAMC)] and biochemical parameters (serum
8% having severe malnutrition [2]. The global preva-total proteins, albumin, prealbumin and transferrin) were sig-
nificantly increased in patients treated with ND. In this group, lence of malnutrition ranges from 18 to 56% in the over-
serum urea nitrogen, urea net excretion and protein equivalent all CAPD population [3–10]. It has been widely docu-
of nitrogen appearance significantly decreased. These facts, mented that malnutrition impairs rehabilitation andtogether with an increase in serum creatinine and no changes
quality of life in dialysis patients, and moreover, thisin dietary intake during the study, suggest a rise in muscle
complication is strongly associated with increased mor-mass related to an anabolic effect of nandrolone decanoate.
Interestingly, serum levels of insulin-like growth factor type 1 bidity and mortality [7, 9–19].
(IGF-1) increased in patients on the androgen group compared Anemia is almost a universal complication of renal
to subjects treated with rHuEPO. Moreover, there was a posi-
failure. Nowadays, recombinant human erythropoietintive and significant correlation between the rise in IGF-1 con-
(rHuEPO) is the prevalent form of therapy in the treat-centrations and the increase in hemoglobin, hematocrit, MAC
and MAMC. ment of this disorder in dialyzed patients. Several studies
on hemodialysis (HD) have reported that correction of
anemia with rHuEPO also may improve the patients’Key words: androgens, erythropoietin, peritoneal dialysis, anemia,
malnutrition, renal replacement therapy. nutritional status [20, 21] and Balaskas et al report similar
results in a CAPD population [22]. However, these find-Received for publication February 13, 2001
ings are contradictory, and other authors did not findand in revised form August 7, 2001
Accepted for publication November 2 2001 significant improvement of nutritional parameters after
rHuEPO therapy [23, 24]. These beneficial effects have 2002 by the International Society of Nephrology
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been considered to be due to an improvement in general body iron stores. Iron supplementation was initiated one
month before the administration of rHuEPO or AND.well being, appetite and physical work capacity rather
Patients were randomized to receive rHuEPO (EPOthan to a specific action of rHuEPO [25].
group) or ND (AND group) as therapy for anemia. Ran-Androgens (AND) were the mainstay in the treatment
domization was carried out using a table of random num-of anemia in dialysis patients in earlier years [26–28], but
bers generated by computer. The EPO group was com-their use has been largely mitigated by the widespread
posed of 14 patients aged between 51 and 70 years (60 availability of rHuEPO. Previous investigations in HD
8, mean  SD) on CAPD for a mean duration of 15 showed that the response of anemia to nandrolone dec-
6 months (range, 8 to 30 months). The etiology of renalanoate (ND) is related to the age of the patients. Thus,
insufficiency was diabetic nephropathy in 10, nephro-in elderly males this response is excellent and similar to
angiosclerosis in 1, chronic glomerulonephritis in 1, andthat obtained with rHuEPO [29, 30]. In a recent non-
unknown etiology in 2 patients. Subjects in this groupcontrolled work, a significant improvement of hemato-
were treated with rHuEPO at an initial dose of 50 U/kg/logic parameters after ND administration was reported
week SC. According to the response of the anemia thisin CAPD patients [31]. Furthermore, at the end of that
dose was modified in order to reach and maintain astudy the serum concentration of total proteins and albu-
hemoglobin concentration between 11 and 13 g/dL. Thir-min significantly increased, suggesting that AND may
teen patients were included in the AND group. Thehave beneficial effects on the nutritional status. The pres-
mean age was 62  7 years (range 51 to 78 years), andent prospective, randomized study was undertaken to
the mean time on CAPD was 17  7 months (10 to 36analyze the correction of anemia in CAPD patients with
months). The primary renal disease was diabetic ne-the use of AND or rHuEPO, and to compare the impact
phropathy in 10 patients, chronic interstitial nephropathyof rHuEPO and ND on the nutritional status of this
in 1, chronic glomerulonephritis in 1 and unknown etiol-population.
ogy in 1. Subjects included in this group were treated
with a six-month cycle of ND (200 mg given once a week
METHODS by IM injection).
All patients were under a standard CAPD regimenPatients
with four or five daily exchanges of 2 or 2.5 liters ofTwenty-nine stable male patients were included in the
dialysate. During the study all subjects were asked to
study. The overall CAPD population consisted of 59
continue undergo the same dietary and dialysis regimen.
patients, 40 males (6 aged below 50 years) and 19 fe-
Mean daily dietary intake was determined from individ-
males. The study was performed during a two-year pe- ual 24-hour food records during a three-day period. The
riod. The eligibility criteria for participation were (a) calorie and protein intake was calculated using a com-
treatment with CAPD for at least six months, (b) male puter software program, Wander (Sandoz Nutricio´n,
gender, and (c) age higher than 50 years. All patients Barcelona, Spain). The dietary protein intake comprised
gave signed informed consent. One patient was discon- between 1 and 1.3 g/kg/day and the energy intake was
tinued because he developed an episode of peritonitis greater than 30 kcal/kg/day.
and another patient was discharged from the study be-
cause he received a renal transplant. The remaining 27 Anthropometric and laboratory measurements
patients completed the study. The mean age was 61  Anthropometric indices included body weight (BW),
7 years (range 51 to 78), and the mean time on dialysis height (H), body mass index [BMI (kg/m2)  BW (kg)/H
16  6 months. Patients had not been previously treated (m)2], triceps skinfold (TSF; mm), mid-arm circumfer-
with rHuEPO, AND, theophylline derivates or steroids, ence (MAC; cm) and midarm muscle circumference
and none of them had received blood transfusions. No (MAMC; cm)  MAC (cm)  3.14  TSF (cm). All
patient was anephric. Patients had no illness requiring measurements were performed by the same investigator
hospitalization or single episode of peritonitis within the in a blinded fashion (that is, the treatment for each pa-
previous three months. Furthermore, before inclusion, tient was unknown) in order to avoid the interpersonal
the possible existence of malignancy, active infections and variations. These parameters were assessed thrice and
immunologic diseases were ruled out. During the study the mean value was recorded. Body weight was measured
period the patients had not any significant intercurrent when dialysis fluid was drained. Patients were examined
illness such as infection, surgery or blood losses. No patient after the drainage of the overnight exchange and before
showed data of iron deficiency. In all cases the serum the morning dialysate was instilled. The MAC was mea-
ferritin concentration was higher than 100 ng/mL and sured at the midpoint between the tip of the acromion
the transferrin saturation was above 20%. All patients and the olecranon process. The TSF was measured using
received oral iron supplements (ferrous sulfate, 210 mg a Holtain skinfold caliper.
Blood samples for carrying out analytical measure-of elemental iron per day) in order to maintain adequate
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Table 1. Baseline demographic, anthropomethric and biochemical data of the patients included in the study
Total group Erythropoietin Androgen
Parameter (N  27) group (N  14) group (N  13)
Age years 617 608 627
Time on dialysis months 166 156 177
Weight kg 66.89 69.210.5 64.16.3
BMI kg/m2 23.73 24.63.6 22.71.7
TSF mm 162.6 16.12.7 15.92.6
MAC cm 26.61.3 26.81.4 26.51.2
MAMC cm 21.61.5 21.71.9 21.50.9
Hematocrit % 26.42.5 25.82.7 272.2
Hemoglobin g/dL 8.70.9 8.50.9 8.90.8
Total proteins g/dL 6.10.4 6.10.5 6.10.3
Albumin g/dL 3.30.4 3.50.4 3.20.3
Pre-albumin mg/dL 307 317 286
Transferrin mg/dL 20257 19653 20862
IGF-1 ng/mL 20554 21359 18629
Creatinine mg/dL 9.22.2 91.8 9.32.5
BUN mg/dL 5311 5312 5211
UNE g/day 9.31.41 9.571.28 91.54
Kt/V 1.980.17 1.950.16 2.030.18
PNA g/kg/day 1.140.21 1.110.27 1.160.09
RRF mL/min 2.41 2.51.1 2.30.9
Abbreviations are: BMI, body mass index; TSF, triceps skinfold; MAC, mid-arm circumference; MAMC, mid-arm muscle circumference; IGF-1, insulin-like growth
factor type 1; BUN, blood urea nitrogen; UNE, urea net excretion; PCR, protein catabolic rate; RRF, residual renal function.
ments were drawn between 9:00 and 10:00 am. Patients sented as the mean  SD. Changes between baseline
fasted from dinner until the completion of blood drawing and follow-up variables within each group were com-
in the morning of the following day. Samples were centri- pared using the Student t test for paired data, and differ-
fuged immediately and the serum was stored at 20C ences between groups were analyzed with the unpaired
until assayed. Levels of insulin-like growth factor-1 Student t test. Univariate correlations between variables
(IGF-1) were determined by radioimmunoassay tech- were evaluated using the Pearson regression analysis. A
nique (Nichols Institute Diagnostics, San Juan Capis- P value less than 0.05 was considered to be statistically
trano, CA, USA). Intra-assay and interassay coefficients significant.
of variation were 3.5 and 8.5%, respectively. Complete
blood cell counts were measured in a Coulter counter,
RESULTSand the serum chemistry determinations were made us-
Demographic, anthropometric and laboratory param-ing habitual automated multichannel analyzer.
eters at baseline of patients included in the study areThe delivered total dose of dialysis was calculated
showed in Table 1. There were no statistically significantusing a 24-hour collection of spent dialysate and a con-
differences in the basal values between the EPO and thecurrent 24-hour urine collection. Peritoneal Kt/V was
AND groups, although the basal serum albumin concen-calculated from a blood urea nitrogen (BUN) measure-
tration in patients of the AND group tended to be lowerment obtained at the end of the 24-period and the dialy-
than in subjects of the EPO group (P  0.06).sate urea collection. Net urea nitrogen excretion (UNE)
The evolution of the serum hemoglobin concentrationwas calculated as the sum of daily dialysate urea nitrogen
and the hematocrit level in the EPO and the AND groupsand urine urea nitrogen. Total body water for urea kinet-
are depicted in Table 2. As expected, these parametersics was estimated using the Watson formula [32]. Resid-
experienced a significant increase in both groups respectual renal function (mL/min) was estimated as the mean
to basal values, reaching statistical significance from theof renal creatinine and renal urea clearances from the
first month of therapy. The mean increase of hemoglobin24-hour urine collection according to Nolph [33]. Protein
and hematocrit was similar in the EPO and the ANDequivalent of nitrogen appearance (PNA) was deter-
groups (3.1  0.9 g/dL and 8.9  2.9%, and 2.9  0.7mined according to the formula of Bergstro¨m, Heim-
g/dL and 8.1 2.4%, respectively). The dose of rHuEPObu¨rger and Lindholm [34].
in the EPO group significantly decreased from 3463 
Statistical analysis 538 U/kg/week at baseline to 2714  1006 U/kg/week at
the end of the study (P  0.01).All statistics were performed with the Statistica soft-
The evolution of anthropometric parameters in bothware for Windows release 5.5 (StatSoft Inc., Tulsa, OK,
USA) on an IBM-compatible computer. Results are pre- groups is shown in Table 3. In the EPO group, only
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Table 4. Evolution of biochemical parameters after six monthsTable 2. Evolution of serum hemoglobin concentration
and hematocrit level in the erythropoietin (EPO) of study in the erythropoietin and the androgen groups
and the androgen (AND) groups
Basal 6th month P value
Hemoglobin g/dL Hematocrit %
Erythropoietin group
Total proteins g/dL 6.10.5 6.30.3b NSaEPO group AND group EPO group AND group
Albumin g/dL 3.50.4 3.60.3b NSa
Basal 8.50.9 8.90.8 25.82.7 272.2 Prealbumin mg/dL 317 326 NSa
1 month 9.20.7 9.50.8 27.82.1 292.4 Transferrin mg/dL 19653 19218b NSa
2 months 9.80.6 100.9 29.51.9 30.42.5 Androgen group
3 months 10.30.5 10.60.7 30.91.6 32.22 Total proteins g/dL 6.10.3 6.70.4b 0.001
4 months 10.80.5 11.10.7 32.41.5 33.52 Albumin g/dL 3.20.3 3.80.2b 0.001
5 months 11.30.5 11.50.5 33.71.4 34.21.7 Prealbumin mg/dL 286 336 0.001
6 months 11.70.6 11.80.4 34.71.6 35.11.5 Transferrin mg/dL 20862 23757b 0.01
The increase in the hemoglobin concentration and the hematocrit level a NS, not significant differences respect to basal valuesreached statistical significance from the first month of therapy in both groups b P  0.05 between the erythropoietin and the androgen groups(P  0.001).
Table 5. Evolution of energy (Cal) and protein (Prot) intake, serumTable 3. Evolution of anthropometric parameters after six months
creatinine (Cr), blood urea nitrogen (BUN), daily net ureaof study in the erythropoietin and the androgen groups
nitrogen excretion (UNE) and protein equivalent of
Basal 6th month P value nitrogen appearance (PNA) after six months of study
in the erythropoietin and the androgen groupsErythropoietin groupa
Weight kg 69.210 69.710 0.05 Basal 6th month P value
BMI kg/m2 24.63.6 24.83.5 0.05
Erythropoietin groupTSF mm 16.12.7 16.42.7 NSb
Calories kcal/kg/day 34.43.5 35.14 NSaMAC cm 26.81.4 271.5 NSb
Protein g/kg/day 1.170.11 1.20.14 NSaMAMC cm 21.71.9 21.82 NSb
Creatinine mg/dL 91.8 8.91.9 NSaAndrogen groupa
BUN mg/dL 5311 5814 NSaWeight kg 64.16.3 65.15.9 0.01
UNE g/day 9.571.28 9.81.3 NSaBMI kg/m2 22.71.7 23.21.6 0.01
PNA g/kg/day 1.110.27 1.180.14 NSaTSF mm 15.92.6 172.4 0.01
Androgen groupMAC cm 26.51.2 27.31.2 0.01
Cal kcal/kg/day 33.83.1 34.13.6 NSaMAMC cm 21.50.9 21.91 0.05
Prot g/kg/day 1.210.09 1.240.11 NSa
Abbreviations are: BMI, body mass index; TSF, triceps skinfold; MAC, mid- Cr mg/dL 9.32.5 9.72.5 0.01arm circumference; MAMC, mid-arm muscle circumference.
BUN mg/dL 5211 4910 0.05a Not significant differences were found at sixth month between groups
UNE g/day 91.54 8.131.73 0.01b Not significant differences respect to basal values
PNA g/kg/day 1.160.09 1.060.11 0.05
a NS, not significant differences respect to basal values
BW and BMI significantly increased respect to baseline.
However, all anthropometric variables experienced a sig-
in the AND group showed a percent increase in thenificant increase in patients included in the AND group.
serum albumin higher than 25%, whereas in six patientsLikewise, biochemical nutritional parameters (serum to-
receiving rHuEPO this parameter decreased.tal proteins, albumin and transferrin) significantly in-
With respect to serum IGF-1 concentrations, this pa-creased in patients treated with AND, but not in subjects
rameter significantly increased in the total group fromin the EPO group (Table 4). At the end of the study, a
205  54 to 219  63 ng/mL (P  0.01). However, whencomparison of nutritional parameters was carried out
each group was analyzed separately, serum IGF-1 valuesbetween both groups. This analysis showed no differ-
rose significantly in patients treated with AND (basal,ences in anthropometric variables. However, biochemi-
198  50 ng/mL; 6th month, 220  64 ng/mL; P  0.05),cal indices (total proteins, albumin and transferrin) were
whereas in the EPO group there was no significant varia-significantly higher in patients treated with AND (Tables
tion (basal, 213  59 ng/mL; 6th month, 217 64 ng/mL).3 and 4).
Basal protein and energy intake were similar in theA relevant finding was related to the evolution of the
EPO and the AND groups. These parameters did notserum albumin concentration. In the overall group, this
experience significant modifications during the studyparameter globally increased by 13%. However, it is
(Table 5). Residual renal function (mL/min) also re-interesting to note that this increment was significant
mained stable (EPO group, basal, 2.5  1.1 and 6thonly in patients receiving ND. The mean percent increase
month, 2.4  1; AND group, basal, 2.3  0.9, 6th month,of serum albumin in patients receiving AND was 21 
2.2  1.1). The dose of dialysis (Kt/V) did not change10% (P  0.001), whereas in subjects treated with
significantly, as it was similar in the EPO and the ANDrHuEPO serum albumin experienced a mean percent
increment of 3.6 10% (NS). Furthermore, four patients groups both at baseline (1.95  0.16 and 2.03  0.18,
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respectively) and after six months (2  0.14 and 2.13  provement in hematologic parameters, and therefore,
AND became the mainstay of anemia therapy in this0.2, respectively). With respect to baseline values, there
were no changes at the end of the study in the total population [26–29]. However, after the introduction of
rHuEPO in the latter 1980s, this form of treatment wasgroup either in the serum concentrations of creatinine
(9.3  2 vs. 9.2  2.2 mg/dL) and BUN (54  13 vs. almost completely abandoned. Recent studies of HD
patients have shown that AND may potentiate the ef-53  11 mg/dL), or in the PNA (1.12  0.14 vs. 1.14 
0.2 g/kg/day) and UNE (9  1.72 vs. 9.3  1.41 g/day). fects of exogenous erythropoietin [35, 36], and moreover,
that the administration of these substances as a uniqueHowever, the AND group showed an increase of serum
creatinine and a reduction of BUN, PNA and UNE. therapy for anemia produce an age-related increase in
hemoglobin and hematocrit levels [37], which is similarDespite that these changes were mild, they reached
statistical significance. Conversely, there was no modifi- to that achieved with the use of rHuEPO [29, 30]. Except
for the results of our preliminary non-controlled studycation of these parameters in patients treated with
rHuEPO (Table 5). [31], to our knowledge, no previous data has been re-
ported on the use of AND in the treatment of anemiaThe evolution of the hemoglobin and hematocrit levels
did not correlate with the changes of the nutritional in CAPD subjects. In that work, we observed that the
hemoglobin concentration and the hematocrit level sig-variables, either in the EPO or AND group. The varia-
tion in the serum IGF-1 concentration did not show any nificantly increased after AND administration. The pres-
ent prospective randomized investigation confirms thoserelationship with the modifications in the hematologic
and nutritional variables in the EPO group. However, previous results, and shows that after six months of treat-
ment, the response of the hematologic parameters inwhen these changes were analyzed in the AND group,
there was a significant positive correlation between the male anemic elderly CAPD patients receiving ND is simi-
lar to that observed in subjects treated with rHuEPO.increment in serum IGF-1 concentrations and the in-
crease in hemoglobin (r 0.64, P 0.05) and hematocrit With both treatments, the mean increase in hemoglobin
and hematocrit levels was higher than 2.5 g/dL and 8%,(r 0.79, P 0.05). Likewise, the change in serum IGF-1
respectively.was significantly correlated with the increase in MAC
The mechanisms by which AND may produce this(r  0.67, P  0.05) and MAMC (r  0.57, P  0.05).
improvement in the response of the anemia is not en-There were no significant correlations between the in-
tirely understood. It has been considered that the eryth-crease in serum IGF-1 and any other anthropometric or
ropoietic response to AND is greatly due to an increasedbiochemical nutritional parameter.
production of EPO (abstract; Yared et al, J Am SocNandrolone decanoate was well tolerated, and no pa-
Nephrol 8:663, 1997). However, in our recent study intient requested withdrawal from the AND group because
HD patients treated with ND this therapy did not pro-of adverse effects. Liver function tests remained stable,
duce an increase of serum EPO levels in all subjects,without elevation of bilirubin and/or hepatic enzymes
and furthermore, there was no relationship between theduring the AND therapy. In the AND group, blood
serum EPO concentration and the response of the ane-pressure increased in one patient (6%), a previously
mia [38]. Other potential mechanisms are the incrementhypertensive subject, while in the EPO group, blood
in the sensitivity of erythroid precursors to EPO [35, 39]pressure increased in four patients (28%, P  0.05 with
or a direct effect of AND on erythropoietic precursorsrespect to the AND group), three of whom were pre-
[39, 40].viously hypertensive and one previously normotensive.
Our present study shows a relevant finding: the in-The increases of blood pressure were mild in all cases and
crease in the serum IGF-1 concentrations and the sig-an adequate control was achieved with antihypertensive
nificant positive association between this increment andtreatment. The main side effects of ND were a rise in
the rise in hemoglobin and hematocrit levels in patientsthe serum concentration of triglycerides and a reduction
treated with ND. In vitro investigations suggest a signifi-in the level of high-density lipoprotein cholesterol, which
cant role for IGF-1 in erythropoiesis by enhancing ery-were mild and transient. By contrast, at the end of the
throid colony formation, maturation and proliferationstudy, the serum concentration of lipoprotein(a) de-
[41, 42]. Moreover, IGF-1 has been nominated as ancreased in subjects receiving AND (from 44 20 to 26
important factor regulating erythropoiesis in uremic pa-16 mg/dL, P  0.001), but not in patients treated with
tients [43]. The results of a recent study by Shih, HuangrHuEPO. No other significant adverse effect of AND
and Li showed that end-stage renal disease (ESRD) pa-on lipid profile was observed.
tients with erythrocytosis had significantly increased se-
rum IGF-1 compared with normal subjects or ESRD
DISCUSSION patients with anemia [44]. Furthermore, the stimulating
Early studies in the 1970s reported that AND adminis- effect of sera from patients with elevated IGF-1 could
be partially blocked by anti-IGF-1. Therefore, it is possi-tration to uremic patients produced a significant im-
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ble to hypothesize that the effects of AND on erythropoi- beneficial in patients with chronic renal failure. Adminis-
tration of ND produced a significant decrease in BUN,esis is mediated, at least in part, by the action of IGF-1.
Prevalence studies in diverse countries have indicated UNE and PNA, suggesting a favorable effect on protein
turnover due to either increased anabolism or decreasedthat a substantial proportion of CAPD patients have
protein-calorie malnutrition [3–10], and most impor- catabolism of dietary or body proteins. It is important
to note that dietary recall did not show any significanttantly, there is strong evidence that malnutrition is an
independent risk factor for morbidity and mortality in change in dietary intake during the study period. Fur-
thermore, serum creatinine concentration experiencedthis population [7, 9–19]. Therefore, a number of inter-
ventions have been proposed for the nutritional manage- a significant increase after ND administration. Taken
together, these findings are strongly suggestive of anment of PD subjects. To our knowledge, the present
study is the first randomized trial designed to prospec- increase in muscle mass related to an anabolic effect of
AND therapy.tively evaluate the impact of the treatment with rHuEPO
or AND on hematologic parameters and nutritional sta- Insulin-like growth factor type 1 is a substance with
significant anabolic properties [48]. Circulating levels oftus in CAPD patients.
Previous reports on HD patients suggested that the this polypeptide are primarily regulated by pulsatile
growth hormone production, although sex steroids playuse of AND might be associated with an improvement
of several nutritional markers [29–31, 37]. Only three an important role in the modulation of IGF-1 secretion.
Human studies have reported that testosterone adminis-previous works have analyzed the effects of AND on
nutritional status in CAPD patients. In 1994, Dombros et tration to adult men, both eugonadal and hypogonadal,
results in increased serum IGF-1 levels [49, 50]. In oural published a retrospective analysis of anabolic steroids
given for at least three months to 13 malnourished study, there was a significant rise in the serum concentra-
tions of IGF-1 (220  64 vs. 198  50 ng/mL, P  0.05)CAPD patients [45]. After this period, the 9 patients
who received ND alone showed a significant increase in after ND administration. In a previous work in healthy
men, Hobbs et al reported that serum IGF-1 tended tothe serum albumin concentration. Kim et al studied 11
patients who received ND for five months, and found increase after therapy with this compound (326  43.2
vs. 300.3  22.4 ng/mL), although this change did notthat this therapy was associated with improvements in
anthropometric measurements, subjective global assess- reach statistical significance [50]. This discrepancy in the
significance of IGF-1 variation might be explained byment scores, protein catabolic rate and serum prealbumin,
transferrin and IGF-1 concentrations, but not albumin the shorter period of treatment in the study by Hobbs
et al (6 weeks) respect to the long-term therapy in our(abstract; Kim et al, J Am Soc Nephrol 8:266, 1997).
Finally, in a very recent study by Johansen et al, 29 trial (6 months). Furthermore, recent studies in animal
models have demonstrated that ND administration pro-dialysis patients were randomized to receive ND (100
mg weekly) or placebo for six months [46]. In the AND duces an increase in muscle IGF-1 mRNA expression
levels [51].group there were 10 patients on HD but only four on
CAPD, and furthermore, no final measurements were Finally, we found a significant direct association be-
tween the increase in serum IGF-1 and the improvementmade in two subjects. Despite these limitations, treat-
ment with ND resulted in an increased lean body mass of some anthropometric parameters. The body distri-
bution of IGF-1 receptors may explain the significantas well as an improved functional status compared with
patients given the placebo. Our results show that ND correlation between the changes in IGF-1 levels and the
variations in MAC and MAMC, as well as the lack ofadministration to CAPD patients is accompanied by a
significant increase in nutritional anthropometric (BW, association with other nutritional parameters. There are
many IGF-1 receptors in skeletal muscle, a target organBMI, TSF, MAC and MAMC) and biochemical indices
(total proteins, albumin, prealbumin and transferrin). for the anabolic effects of IGF-1. In animal models, re-
combinant human IGF-1 stimulates protein synthesisHowever, only BW and BMI significantly increased in
patients treated with rHuEPO, whereas after six months and suppresses protein degradation in skeletal muscle
[52]. Therefore, a proportion of the anabolic effects ofof therapy the remaining variables did not change sig-
nificantly. ND in the patients in our study might be mediated by
protein accrual in skeletal muscle. On the contrary, it isIt is clearly demonstrated that AND therapy possesses
evident anabolic effects that stimulate nitrogen reten- possible that the anabolic actions of IGF-1 do not include
stimulation of hepatic protein synthesis, which may betion, weight gain and muscle increase. These beneficial
properties are the background for their use in treating due to the fact that there are very few IGF-1 receptors
in the liver [53]. These findings suggest that the effectswasting in patients with several chronic illness, including
cirrhosis, pulmonary diseases, burns, and HIV infection of AND on protein synthesis may be mediated by other
mechanisms independent of IGF-1.[47]. The results of our work are in agreement with
previous studies [45, 46] and suggest that AND also are Early leucine-kinetic studies by Esposito, Pluvio and
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and nutrition in continuous ambulatory peritoneal dialysis: Associ-Giordano in patients with nephrosis or renal insuffi-
ation with clinical outcomes. J Am Soc Nephrol 7:198–207, 1996
ciency showed that the amount of leucine incorporated 10. Palop L, Vega N, Rodrı´guez T, et al: Nutritional status of CAPD
patients at three years. Perit Dial Int 16(Suppl 1):S195–S202, 1996into the plasma albumin fraction was significantly in-
11. Acchiardo SR, Moore LW, Latour PA: Malnutrition as the maincreased after anabolic agents administration, demonstra-
factor in morbidity and mortality of dialysis patients. Kidney Int
ting that AND stimulate protein synthesis [54]. However, 24(Suppl 16):S199–S203, 1983
12. Maiorca R, Vonesh EF, Cavalli PL, et al: A multicenter, selec-to date the intimal mechanisms of this action remain
tion-adjusted comparison of patient and technique survivals onunknown. In this setting, it is important to take into
CAPD and hemodialysis. Perit Dial Int 114:118–127, 1991
account that human liver contains the classical AND 13. Kopple J: Effect of malnutrition on morbidity and mortality in
maintenance dialysis patients. Am J Kidney Dis 24:1002–1009, 1994receptor [55, 56]. Therefore, it is speculated that AND
14. Ikizler T, Hakim R: Nutrition in end-stage renal disease. Kidneystimulate hepatic protein synthesis through an androgen Int 50:343–357, 1996
receptor-mediated mechanism that is unrelated to IGF-1, 15. Fung L, Pollock C, Caterson R, et al: Dialysis adequacy and
nutrition determine prognosis in continuous ambulatory peritonealeven by a direct effect on mRNA expression. On the
dialysis patients. J Am Soc Nephrol 7:737–744, 1996other hand, it is impossible to rule out that this effect 16. Avram MM, Goldwasser P, Erroa M, Fein PA: Predictors of
may be mediated through nonclassical binding sites, or survival in continuous ambulatory peritoneal dialysis patients: The
importance of prealbumin and other nutritional and metabolicthat it could be modulated by a number of other factors
markers. Am J Kidney Dis 23:91–98, 1994
including genetic background, cytokines, hormones, etc. 17. Avram MM, Fein PA, Bonomi L, et al: Predictors of survival in
continuous ambulatory peritoneal dialysis patients: A five-yearIn conclusion, ND may be considered a valid alterna-
prospective study. Perit Dial Int 16(Suppl 1):S190–S194, 1996tive therapy for anemia in elderly male CAPD patients,
18. Chung SH, Lindholm B, Lee HB: Influence of nutritional status
with similar results to that of rHuEPO. Furthermore, on continuous ambulatory peritoneal dialysis patient survival. Perit
Dial Int 20:19–26, 2000conversely to this recombinant hormone, androgenic
19. Dombros NV, Digenis GE, Oreoupoulos DG: Is malnutrition atherapy has benefitial actions on nutritional status, with
problem for the patient on peritoneal dialysis? Nutritional markers
significant improvement of both anthropometric and bio- as predictors of survival in patients on CAPD. Perit Dial Int
15(Suppl):S10–S19, 1995chemical parameters. These effects on hematologic and
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netic modeling analysis. Blood Purif 8:301–308, 1990
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